Assessing Thromboembolic Complications and In-Hospital Mortality and Clinical Factors Affecting Thromboembolic Complications in COVID-19 stage 3-5 ICU cases
Background: Thromboembolic (TE) complications are associated with the severity of the infection and are no less of a disease that contributes to the fatality of critically ill patients infected with COVID-19. Objective: This study aimed to investigate the prevalence of TE complications, in-hospital...
Published in: | Journal of Research in Pharmacy |
---|---|
Main Author: | |
Format: | Article |
Language: | English |
Published: |
Marmara University
2024
|
Online Access: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85201800329&doi=10.29228%2fjrp.805&partnerID=40&md5=0ec5af944e63899981969362c6294d37 |
id |
2-s2.0-85201800329 |
---|---|
spelling |
2-s2.0-85201800329 Wan Rosli W.N.M.; Ravi T.; Ming L.C.; Zulkifly H.H. Assessing Thromboembolic Complications and In-Hospital Mortality and Clinical Factors Affecting Thromboembolic Complications in COVID-19 stage 3-5 ICU cases 2024 Journal of Research in Pharmacy 28 4 10.29228/jrp.805 https://www.scopus.com/inward/record.uri?eid=2-s2.0-85201800329&doi=10.29228%2fjrp.805&partnerID=40&md5=0ec5af944e63899981969362c6294d37 Background: Thromboembolic (TE) complications are associated with the severity of the infection and are no less of a disease that contributes to the fatality of critically ill patients infected with COVID-19. Objective: This study aimed to investigate the prevalence of TE complications, in-hospital mortality, and risk factors among ICU patients (stage 3, 4, 5) infected with COVID-19. Methodology: In this retrospective single-center cross-sectional study, 106 severe patients referred to intensive care units (ICUs) due to COVID-19 between February 2021 and December 2022 were included. All patients received a thromboprophylaxis agent. Results: Mean (SD) age 49.81(13.27), 50.9% were male, 68.9% Malays, mean (SD) (2-12) days of ICU admission with the most coexisting comorbidities being hypertension (44.3%), diabetes mellitus (33%), and obesity (60.3%). Of 106 patients, 51 (41.9%) developed pulmonary embolism (PE) and 27.5% died despite adequate thromboprophylaxis. In total, 51 (41.9%) developed TE event during their ICU admission. Significantly higher proportions of COVID-19 patients who developed complications of PE (77.8% vs 42%; p = 0.006) died. D-dimer, fibrinogen, white cell count (WCC), and troponin were significantly greater among those with TE events. Demographics, co-morbidities, other laboratory parameters and were similar in COVID-19 patients with and without TE events. Conclusion: There is a high incidence of TE complications and in-hospital mortality in critically ill patients with COVID-19. A high level of D-dimer, fibrinogen, white cell count, and troponin were associated with in-hospital TE events. It is apparent that routine chemical thromboprophylaxis may not be sufficient to prevent TE complications in patients with severe COVID-19. © 2023 Marmara University Press. Marmara University 26306344 English Article All Open Access; Gold Open Access |
author |
Wan Rosli W.N.M.; Ravi T.; Ming L.C.; Zulkifly H.H. |
spellingShingle |
Wan Rosli W.N.M.; Ravi T.; Ming L.C.; Zulkifly H.H. Assessing Thromboembolic Complications and In-Hospital Mortality and Clinical Factors Affecting Thromboembolic Complications in COVID-19 stage 3-5 ICU cases |
author_facet |
Wan Rosli W.N.M.; Ravi T.; Ming L.C.; Zulkifly H.H. |
author_sort |
Wan Rosli W.N.M.; Ravi T.; Ming L.C.; Zulkifly H.H. |
title |
Assessing Thromboembolic Complications and In-Hospital Mortality and Clinical Factors Affecting Thromboembolic Complications in COVID-19 stage 3-5 ICU cases |
title_short |
Assessing Thromboembolic Complications and In-Hospital Mortality and Clinical Factors Affecting Thromboembolic Complications in COVID-19 stage 3-5 ICU cases |
title_full |
Assessing Thromboembolic Complications and In-Hospital Mortality and Clinical Factors Affecting Thromboembolic Complications in COVID-19 stage 3-5 ICU cases |
title_fullStr |
Assessing Thromboembolic Complications and In-Hospital Mortality and Clinical Factors Affecting Thromboembolic Complications in COVID-19 stage 3-5 ICU cases |
title_full_unstemmed |
Assessing Thromboembolic Complications and In-Hospital Mortality and Clinical Factors Affecting Thromboembolic Complications in COVID-19 stage 3-5 ICU cases |
title_sort |
Assessing Thromboembolic Complications and In-Hospital Mortality and Clinical Factors Affecting Thromboembolic Complications in COVID-19 stage 3-5 ICU cases |
publishDate |
2024 |
container_title |
Journal of Research in Pharmacy |
container_volume |
28 |
container_issue |
4 |
doi_str_mv |
10.29228/jrp.805 |
url |
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85201800329&doi=10.29228%2fjrp.805&partnerID=40&md5=0ec5af944e63899981969362c6294d37 |
description |
Background: Thromboembolic (TE) complications are associated with the severity of the infection and are no less of a disease that contributes to the fatality of critically ill patients infected with COVID-19. Objective: This study aimed to investigate the prevalence of TE complications, in-hospital mortality, and risk factors among ICU patients (stage 3, 4, 5) infected with COVID-19. Methodology: In this retrospective single-center cross-sectional study, 106 severe patients referred to intensive care units (ICUs) due to COVID-19 between February 2021 and December 2022 were included. All patients received a thromboprophylaxis agent. Results: Mean (SD) age 49.81(13.27), 50.9% were male, 68.9% Malays, mean (SD) (2-12) days of ICU admission with the most coexisting comorbidities being hypertension (44.3%), diabetes mellitus (33%), and obesity (60.3%). Of 106 patients, 51 (41.9%) developed pulmonary embolism (PE) and 27.5% died despite adequate thromboprophylaxis. In total, 51 (41.9%) developed TE event during their ICU admission. Significantly higher proportions of COVID-19 patients who developed complications of PE (77.8% vs 42%; p = 0.006) died. D-dimer, fibrinogen, white cell count (WCC), and troponin were significantly greater among those with TE events. Demographics, co-morbidities, other laboratory parameters and were similar in COVID-19 patients with and without TE events. Conclusion: There is a high incidence of TE complications and in-hospital mortality in critically ill patients with COVID-19. A high level of D-dimer, fibrinogen, white cell count, and troponin were associated with in-hospital TE events. It is apparent that routine chemical thromboprophylaxis may not be sufficient to prevent TE complications in patients with severe COVID-19. © 2023 Marmara University Press. |
publisher |
Marmara University |
issn |
26306344 |
language |
English |
format |
Article |
accesstype |
All Open Access; Gold Open Access |
record_format |
scopus |
collection |
Scopus |
_version_ |
1809678473529131008 |